New drug duo aims to tame aggressive blood cancers
NCT ID NCT04874194
Summary
This study tested whether combining two drugs, omacetaxine and venetoclax, could help control acute myeloid leukemia or myelodysplastic syndrome that had returned or stopped responding to other treatments in patients with a specific genetic change called RUNX1. The goal was to find the safest, most effective dose and see if the combination could reduce or eliminate cancer cells. The trial was terminated early and enrolled 24 adult participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.